These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29405820)

  • 1. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
    Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproate augments Niraparib killing of tumor cells.
    Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
    Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
    Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
    Booth L; Roberts J; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
    Dent P; Booth L; Poklepovic A; Kirkwood JM
    Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
    Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
    Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neratinib augments the lethality of [regorafenib + sildenafil].
    Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
    J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Front Oncol; 2019; 9():650. PubMed ID: 31380285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
    Roberts JL; Poklepovic A; Booth L; Dent P
    Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
    Booth L; Poklepovic A; Dent P
    Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody
    Booth L; Roberts JL; Poklepovic A; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Oncotarget; 2017 Oct; 8(52):90262-90277. PubMed ID: 29163826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niraparib: A Review in Ovarian Cancer.
    Heo YA; Duggan ST
    Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
    Rimel BJ; Dockery L; Randall LM; Moore K
    Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
    Booth L; Roberts JL; Spiegel S; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):597-607. PubMed ID: 30388910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.
    Tavallai M; Booth L; Roberts JL; Poklepovic A; Dent P
    Front Oncol; 2016; 6():142. PubMed ID: 27379204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
    Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
    Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.